Glossary · Sectors
Health and life sciences monitoring: regulation, science and competition on a single radar
Health and life sciences monitoring is the continuous tracking of the regulation, scientific evidence, clinical trials, competitors and funding that condition the development and market access of a medicine or a medical device. In October 2026 the transition periods of the medical device regulations run to 2027–2029, a proposal to simplify them is under way, the pharmaceutical package is still pending in the European Parliament, and joint health technology assessment is expanding.
Health Biomedical laboratory
What European regulatory timetable affects health and life sciences?
In this sector several reforms advance at once and at different stages: some already apply, others have transition periods, and others are still under negotiation. Situation in October 2026:
| Rule or reform | What changes | Key dates | Status |
|---|---|---|---|
| Medical devices, Regulation (EU) 2017/745 (MDR), amended by 2023/607 | Extends the transition for certificates under the former directive, subject to conditions: a quality system and an application to a notified body before 26 May 2024, and a signed agreement before 26 September 2024[1] | 2027 for class III and implantable IIb; 2028 for the rest of IIb, IIa, Is and Im | In transition |
| In vitro diagnostics, Regulation (EU) 2017/746 (IVDR), amended by 2024/1860 | Staggered transition by class, and mandatory notice, at least six months in advance, of supply interruptions that may cause serious harm. Eudamed modules become mandatory six months after the Commission publishes the functionality notice for each one[2] | 31 December 2027 (class D), 2028 (class C) and 2029 (class B and sterile class A). Interruption notice from 10 January 2025 | In transition |
| Targeted revision of the MDR and IVDR, procedure 2025/0404(COD) | The Commission’s proposal of December 2025 to simplify procedures and reduce burdens | Draft report in the Parliament’s SANT committee on 1 July 2026; plenary vote expected around the turn of the year[3] | Under way |
| Health technology assessment, Regulation (EU) 2021/2282 | Joint clinical assessments at European level, which feed national price and reimbursement decisions. Class IIb and III medical devices and class D diagnostic devices are selected by implementing act[4] | Oncology medicines with new active substances and advanced therapies from 12 January 2025; orphan medicines from 13 January 2028; the rest from 13 January 2030 | Applied in phases |
| Pharmaceutical package (directive and regulation) | Eight years of data protection and market protection that can be extended to a maximum of eleven years, or twelve with the transferable exclusivity voucher for priority antimicrobials; supply obligations to prevent shortages[5] | Adopted by the Council on 28 September 2026 | Pending adoption by Parliament and publication in the Official Journal |
| Critical Medicines Act | Resilience requirements in public procurement of critical medicines, joint purchasing between Member States and contingency stockpiles[6] | Provisional agreement on 12 May 2026 | Pending formal adoption |
| European Health Data Space, Regulation (EU) 2025/327 | Cross-border exchange of clinical data (primary use) and access to data for research and innovation (secondary use)[7] | Implementing acts in March 2027; patient summary, electronic prescription and most secondary use in March 2029; medical imaging, laboratory results and discharge reports in March 2031 | In force since 26 March 2025 |
| AI Act, Regulation (EU) 2024/1689 | High-risk obligations for AI integrated in regulated products, such as software that is a medical device[8] | 2 August 2028, after the amendment by the digital omnibus | Date amended |
Which sources to watch in health and life sciences
It is worth distinguishing three families of source, because they answer different questions and move at different paces:
- Regulatory: what is binding and from when. The Official Journal of the EU and the BOE; the European Medicines Agency (EMA), with its opinions and guidance; the Spanish Agency for Medicines and Health Products (AEMPS), which publishes alerts, information notes, supply problems and the CIMA database of authorised medicines[9]; and the Commission’s implementation pages.
- Scientific and clinical: what works and what is coming. Literature on PubMed; trials on the European CTIS system, whose public search allows authorised trials under Regulation (EU) 536/2014 to be consulted[10], and on the AEMPS’s Spanish Register of Clinical Studies (REEC); congresses in each therapeutic area.
- Competitive: who is moving and where. Authorisations and withdrawals, press releases, patents and supplementary protection certificates, hospital tenders and licensing agreements.
Which decisions rely on this watch?
- Prioritising the product portfolio. A competitor’s trial in an advanced phase, or a joint clinical assessment in the same indication, changes the expected value of a development.
- Planning certification. The transition deadline for each class of medical device, the availability of notified bodies and the ongoing MDR review.
- Preparing market access. Which comparators and criteria the joint assessment uses, and what the new regulatory protection will require.
- Securing supply. Interruption notices, shortages published by the AEMPS, and the new obligations of the Critical Medicines Act.
- Seeking funding and partners. Calls, consortia and clinical groups publishing in your area.
How to read a regulatory signal in health
- Place the signal in its stage: proposal, provisional agreement, adoption, publication or application. The pharmaceutical package, for example, has already passed the agreement and the Council’s adoption, but it is not binding until it is published.
- Identify which products it affects: risk class, type of medicine (orphan, advanced therapy, antimicrobial), use of AI.
- Look for the implementing act or the guidance that sets the details, since operational deadlines usually sit there.
- Cross-check with the scientific or competitive source: who in your area is affected before you are?
- Record the regulatory team’s interpretation next to the source, so that it is not redone for the next product.
How Innguma runs health watching
Innguma monitors news and websites, patents, regulation and the BOE, tenders, competitors’ websites and specialist sources; the exact set of sources for each therapeutic area or technology is defined with each organisation. In Factory, the space where Innguma processes and structures signals, the AI groups duplicates and classifies each signal by category, technology, entity, type of event, place and tone, and each one keeps the link to its source. In such a regulated sector, expert reading is essential: people decide what is watched, what is published and who receives it, and what is validated is kept in the Library as a searchable history.
Use case
How the day-to-day changes
- Agencies, official gazettes and scientific databases are reviewed separately and by hand.
- Changes to a reform's timetable are learnt about at a congress or from a consultancy.
- Regulatory interpretations stay in emails and are not reused.
- When reviewing the inbox
A news item on the MDR review arrives classified by rule and product type, alongside earlier signals on that procedure.
- Weekly
A newsletter for regulatory and medical management with regulation, competitors' trials and supply alerts, each signal with its source.
- Before prioritising the portfolio
The history of the indication in the Library: authorisations, trials, assessments and the team's comments.
Each reform is followed in stages, with its application date.
A competitor's trial or authorisation is read alongside what was already known about it.
The team's interpretation sits next to the source, for the next product.
- Monitoring of regulation and Spain's Official State Gazette (BOE), agency and competitor websites, patents, tenders and specialist sources in the therapeutic area.
- AI classification by category, technology, entity, type of event, place and tone, with the source always linked.
- Library with tags and comments, and newsletters with AI-prepared summaries reviewed by the team.
The regulatory, clinical and scientific assessment is your team's. Innguma gathers, organises and keeps; the decisions on product and market access are yours.
- A watch on the review of the MDR and IVDR and their transition periods
- A watch on competitors' trials and authorisations in your indication
- A watch on joint clinical assessments and market access
Illustrative example of a typical use.
Sources and references
- [1] HPRA, Irish medical devices regulator. MDR transitional provisions following Regulation (EU) 2023/607
- [2] Regulation (EU) 2024/1860 amending Regulations (EU) 2017/745 and 2017/746 (Eudamed, supply interruption and IVDR transition). EUR-Lex. 2024
- [3] Mondaq. How will the EU Parliament shape the MDR/IVDR revision? 7 August 2026
- [4] Regulation (EU) 2021/2282 on health technology assessment, Article 7. EUR-Lex. 2021
- [5] Council of the EU. The Council adopts the pharma package. 28 September 2026
- [6] Council of the EU. Critical Medicines Act: provisional agreement between Council and Parliament. 12 May 2026
- [7] European Commission. European Health Data Space Regulation: application timetable
- [8] European Commission, AI Act Service Desk. Timeline for the application of the AI Regulation
- [9] Spanish Agency for Medicines and Health Products (AEMPS)
- [10] European Medicines Agency. Clinical Trials Information System (CTIS)